Guanylurea metformium double salt of decavanadate, (HGU+)4(HMet+)2(V10O286−)·2H2O

Bis{[amino(iminiumyl)methyl]urea} tetrakis{2-[(dimethylamino)(iminiumyl)methyl]guanidine} di-μ6-oxido-tetra-μ3-oxido-tetradeca-μ2-oxido-octaoxidodecavanadium(V) tetrahydrate

In the crystal structure of the title compound, numerous N—H⋯O and O—H⋯O hydrogen bonds of medium strengths connect metforminium and guanylurea cations and centrosymmetric deca­vanadate(V) anions into a three-dimensional network structure.

The title compound, (C₄H₁₂N₅)₄(C₂H₇N₄O)₂[V₁₀O₂₈]·4H₂O, is a by-product obtained by reacting ammonium metavanadate(V), metformin hydro­chloride and acetic acid in the presence of sodium hypochlorite, at pH = 5. The crystal structure comprises a deca­vanadate(V) anion (V₁₀O₂₈)^6– lying on an inversion centre in space group P, while cations and solvent water mol­ecules are placed in general positions, surrounding the anion, and forming numerous N—H⋯O and O—H⋯O hydrogen bonds. Metforminium (C₄H₁₂N₅)⁺ and guanylurea (C₂H₇N₄O)⁺ cations display the expected shape. Inter­estingly, in physiology the latter cation is known to be the main metabolite of the former one. The reported structure thus supports the role of sodium hypochlorite as an oxidizing reagent being able to degrade metformin hydro­chloride to form guanylurea.

A Versatile Polyoxovanadate in Diverse Cation Matrices: A Supramolecular Perspective

A series of decavanadate based compounds, formulated as [Co(H₂O)₆][{Na₄(H₂O)₁₄}{V₁₀O₂₈}]·4H₂O (1), [Zn(H₂O)₆][Na₃(H₂O)₁₄] [HV₁₀O₂₈]·4H₂O (2), [HMTAH]₂ [{Zn(H₂O)₄}₂{V₁₀O₂₈}]·2H₂O (3), [{Co(3-amp)(H₂O)₅}]₂ [3-ampH]₂ [V₁₀O₂₈] · 6H₂O (4), [4-ampH]₁₀[{Na(H₂O)₆}{HV₁₀O₂₈}][V₁₀O₂₈]·15H₂O (5), [{4-ampH}₆ {Co(H₂O)₆}₃][V₁₀O₂₈]₂·14H₂O (6), and [{4-ampH}₁₀{Zn(H₂O)₆}][V₁₀O₂₈]₂·10H₂O (7), have been synthesized (where HMTAH = mono-protonated hexamethylenetetramine, 3-ampH = protonated 3-amino pyridine and 4-ampH= protonated 4-aminopyridine) from the relevant aqueous sodium-vanadate solution, by varying the pH of the solution and amino pyridine/hexamine derivatives as well as transition metal salts (Co(II)- and Zn(II)-salts). In this series of compounds 1-7, the polyoxovanadate (POV) cluster [V₁₀O₂₈]^6- is the common cluster anion, stabilized by diverse cations. The diverse supramolecular patterns around the decavanadate cluster anion in different cationic matrices have been described to understand the microenvironment in the decavanadate-based minerals. All of these compounds have solvent water molecules in their respective crystal lattices. Since water can interact directly with cations and anions, providing an additional stability and structural diversity, we have analyzed supramolecular water structures in all these compounds to comprehend the role of the lattice water in the formation of natural decavanadate containing minerals. Compounds 1-7, that are isolated at an ambient condition from aqueous solution, are characterized by routine spectral analysis, elemental analyses and finally unambiguously by single crystal X-ray crystallography.

Decavanadate Salts of Cytosine and Metformin: A Combined Experimental-Theoretical Study of Potential Metallodrugs Against Diabetes and Cancer

Cytosine, a DNA and RNA building-block, and Metformin, the most widely prescribed drug for the treatment of Type 2 Diabetes mellitus were made to react separately with ammonium or sodium metavanadates in acidic aqueous solutions to obtain two polyoxovanadate salts with a 6:1 ratio of cation-anion. Thus, compounds [HCyt]6[V10O28]·4H2O, 1 and [HMetf]6[V10O28]·6H2O, 2 (where HCyt = Cytosinium cation, [C4H6N3O]+ and HMetf = Metforminium cation, [C4H12N5]+) were obtained and characterized by elemental analysis, single crystal X-ray diffraction, vibrational spectroscopy (IR and Raman), solution 51V-NMR, thermogravimetric analysis (TGA-DTGA), as well as, theoretical methods. Both compounds crystallized in P1 ¯   space group with Z' = 1/2, where the anionic charge of the centrosymmetric ion [V10O28]6- is balanced by six Cytosinium and six Metforminium counterions, respectively. Compound 1 is stabilized by π-π stacking interactions coming from the aromatic rings of HCyt cations, as denoted by close contacts of 3.63 Å. On the other hand, guanidinium moieties from the non-planar HMetf in Compound 2 interact with decavanadate μ2-O atoms via N-H···O hydrogen bonds. The vibrational spectroscopic data of both IR and Raman spectra show that the dominant bands in the 1000-450 cm-1 range are due to the symmetric and asymmetric ν(V-O) vibrational modes. In solution, 51V-NMR experiments of both compounds show that polyoxovanadate species are progressively transformed into the monomeric, dimeric and tetrameric oxovanadates. The thermal stability behavior suggests a similar molecular mechanism regarding the loss of water molecules and the decomposition of the organic counterions. Yet, no changes were observed in the TGA range of 540-580°C due to the stability of the [V10O28]6- fragment. Dispersion-corrected density functional theory (DFT-D) calculations were carried out to model the compounds in aqueous phase using a polarized continuum model calculation. Optimized structures were obtained and the main non-covalent interactions were characterized. Biological activities of these compounds are also under investigation. The combination of two therapeutic agents opens up a window toward the generation of potential metalopharmaceuticals with new and exciting pharmacological properties.

Confinement Effects on Chemical Equilibria: Pentacyano(Pyrazine)Ferrate(II) Stability Changes within Nanosized Droplets of Water

Nanoscale confinement is known to impact properties of molecules and we observed changes in the reactivity of an iron coordination complex, pentacyano(pyrazine)ferrate(II). The confinement of two coordination complexes in a sodium AOT/isooctane reverse micellar (RM) water droplet was found to dramatically increase the hydrolysis rate of [Fe(CN)₅pyz]3- and change the monomer-dimer equilibria between [Fe(CN)₅pyz]3- and [Fe₂(CN)10pyz]6-. Combined UV-Vis and ¹H-NMR spectra of these complexes in RMs were analyzed and the position of the monomer-dimer equilibrium and the relative reaction times were determined at three different RM sizes. The data show that the hydrolysis rates (loss of pyrazine) are dramatically enhanced in RMs over bulk water and increase as the size of the RM decreases. Likewise, the monomer-dimer equilibrium changes to favor the formation of dimer as the RM size decreases. We conclude that the effects of the [Fe(CN)₅pyz]3- stability is related to its solvation within the RM.

Size and shape trump charge in interactions of oxovanadates with self-assembled interfaces: application of continuous shape measure analysis to the decavanadate anion

Using ⁵¹V NMR spectroscopy, dynamic light scattering and continuous shape analysis to characterize two polyoxometalate-encapsulation in reverse micelles.

Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model

Because of the increasing global spread of type 2 diabetes mellitus, there is a need to develop new antidiabetic agents. Recently we have synthesized new decavanadates using metformin as counterion. In particular, the compound containing three metforminium dications has been obtained in high yield and has been completely characterized. Biological studies using Wistar rats that have been fed with a high caloric diet inducing insulin resistance and metabolic syndrome were carried out. Results of the impact on key biochemical parameters mediated by metformin alone and the new compound are here presented. The metforminium decavanadate (H2Metf)3[V10O28]·8H2O, abbreviated as Metf-V10O28, was shown to have pharmacological potential as a hypoglycemic, lipid-lowering and metabolic regulator, since the resulting compound made of the two components with antidiabetic activities, reduces both dosage and time of administration (twice a week). Hence, due to the beneficial effects induced by the metforminium decavanadate we recommend to continue the exploration into the mechanism and toxicology of this new compound.